After oral administration to healthy subjects, the mean terminal elimination half-life
was 33 hours (21 to 54 hours for 5th to 95th percentile) and the mean olanzapine
plasma clearance was 26L/hr (12 to 47L/hr for the 5th to 95th percentile). Olanzapine
pharmacokinetics varied on the basis of smoking status, gender and age.
In female versus male subjects, the mean elimination half-life was somewhat
prolonged (36.7hr vs 32.3hr) and the clearance was reduced (18.9L/hr vs 27.3L/hr).
However, olanzapine (5-20mg) demonstrated a comparable safety profile in female (n
= 467) as in male patients (n = 869).
Smoking induces the CYP1A2 metabolism of olanzapine. Therefore, in smokers the
clearance of olanzapine is higher, on average, than the clearance in non-smokers.
TGA eBS - Product and Consumer Medicine Information Licence